期刊
NATURE GENETICS
卷 45, 期 12, 页码 1439-U189出版社
NATURE PORTFOLIO
DOI: 10.1038/ng.2822
关键词
-
资金
- Damon Runyon Cancer Research Foundation
- Louis V. Gerstner Jr. Young Investigator Award
- Starr Cancer Consortium
- Geoffrey Beene Cancer Research Center
- Argonne Leadership Computing Facility at the Argonne National Laboratory
- Office of Science of the US Department of Energy [DE-AC02-06CH1135]
- Toyota Technological Institute at Chicago
Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition. However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting. We conducted a comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases. These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations. Molecular dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor. Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists. These data implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据